Absci Publicly Traded Corporation
Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com.
Investors
%20LLC.png)
Total Funding:
394259989
Founded Date:
2011-01-01
Employee Number:
101-250
Last Funding Date:
2025-07-24
Headquarters:
Vancouver,Washington,United States,North America
Funding Stage:
IPO
Funding Total Value:
394259989
Last Funding Total Usd:
50000000
Last Funding Total Currency:
USD
Last Funding Total Value:
50000000
Founders:
Sean McClain
Phone Number:
360-949-1041
Stock Symbol:
ABSI
City:
Vancouver
Region:
Washington
Country:
United States